Skip to main content
. Author manuscript; available in PMC: 2012 Sep 19.
Published in final edited form as: Cancer Chemother Pharmacol. 2010 Oct 28;68(2):379–388. doi: 10.1007/s00280-010-1481-z

Fig. 2.

Fig. 2

QRT-PCR analysis of RRM1, RRM2, and RRM2b represents fold change in RRM1, RRM2, and RRM2b mRNA expression in peripheral blood mononuclear cells 24-h post-treatment with 3-AP plus gemcitabine in patients 4, 16, 27 and 31. Fold change is relative to pre-treatment sample, and all samples were normalized to TATA-binding protein (TBP). There was a quantitative decrease in PBMC RRM2 mRNA expression after 3-AP/gemcitabine therapy in 3 of 4 patients evaluated, and variable effects observed in RRM1 and RRM2b